Tau imaging: early progress and future directions.

By V. Villemagne, Michelle T. Fodero-Tavoletti, Colin L. Masters, C. Rowe. 2015

465 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Visual Feature Attribution Using Wasserstein GANs (2017, background): “Furthermore, it is known that in later stages of the disease other brain areas such as the temporal lobe get affected as well [58].”
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease (2017, background): “The recent advent of tauspecific positron emission tomography (PET) tracers now allows assessment of regional tau load in the living human brain (Dani et al., 2016; Saint-Aubert et al., 2017; Villemagne et al., 2015), which will provide new insights into the etiology of AD, and help diagnostic accur”
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016, background): “First, available evidence points to recently developed tau PET tracers as useful measures of neurofibrillary tangles in AD, while utility in non-AD tauopathies has not yet been clarified.(8,9) Elevated tau PET tracer signal, particularly in neocortical regions, is highly associated with the”
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. (2016, background): “Understanding which protein is the major force driving neurodegeneration and cognitive decline is highly relevant for developing and testing effective therapies, and the advent of novel tau PET tracers (Villemagne et al., 2015) will for the first time allow indepth testing of the entire amyloid casc”